Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
Broadly protective vaccines against known and pre-emergent coronaviruses are urgently needed. Critical to their development is a deeper understanding of cross-neutralizing antibody responses induced by natural human coronavirus (HCoV) infections. Here, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a new target for the rational design of pan-sarbecovirus vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 16. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wec, Anna Z [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.05.15.096511 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310908078 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310908078 | ||
| 003 | DE-627 | ||
| 005 | 20240214232218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.05.15.096511 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM310908078 | ||
| 035 | |a (NLM)32511337 | ||
| 035 | |a (PII)2020.05.15.096511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wec, Anna Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Broadly protective vaccines against known and pre-emergent coronaviruses are urgently needed. Critical to their development is a deeper understanding of cross-neutralizing antibody responses induced by natural human coronavirus (HCoV) infections. Here, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a new target for the rational design of pan-sarbecovirus vaccines | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Wrapp, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Herbert, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Maurer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Haslwanter, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Sakharkar, Mrunal |e verfasserin |4 aut | |
| 700 | 1 | |a Jangra, Rohit K |e verfasserin |4 aut | |
| 700 | 1 | |a Dieterle, M Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Lilov, Asparouh |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Deli |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Longping V |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Nicole V |e verfasserin |4 aut | |
| 700 | 1 | |a Hsieh, Ching-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nianshuang |e verfasserin |4 aut | |
| 700 | 1 | |a Nett, Juergen H |e verfasserin |4 aut | |
| 700 | 1 | |a Champney, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Burnina, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Sinclair, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Pudi, Sarat |e verfasserin |4 aut | |
| 700 | 1 | |a Bortz, Robert |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Wirchnianski, Ariel S |e verfasserin |4 aut | |
| 700 | 1 | |a Laudermilch, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Florez, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Fels, J Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a O'Brien, Cecilia M |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Barney S |e verfasserin |4 aut | |
| 700 | 1 | |a Nemazee, David |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, Dennis R |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 700 | 1 | |a Voss, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Chandran, Kartik |e verfasserin |4 aut | |
| 700 | 1 | |a Dye, John M |e verfasserin |4 aut | |
| 700 | 1 | |a McLellan, Jason S |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Laura M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 16. Mai |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:16 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.05.15.096511 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 16 |c 05 | ||